Compare Figs Inc (FIGS) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs Tango Therapeutics Inc. — how do they compare? Figs Inc trades at $18.6 (market cap $3.10B), while Tango Therapeutics Inc. trades at $22.2 (market cap $3.74B). The key difference: Tango Therapeutics Inc. is the larger of the two by market cap, and Figs Inc is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Figs Inc for 31 Days and Tango Therapeutics Inc. for 0 Days on average.
| FIGS | TNGX | |
|---|---|---|
Market Cap | $3.10B | $3.74B |
Volume | 5,758,739 | 3,438,781 |
Sector | Consumer Cyclical | Health |
52-Week High | $18.63 | $32.90 |
52-Week Low | $7.38 | $7.50 |
Typical Hold Time | 31 Days | 0 Days |
Enterprise Value | $2.86B | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS trades at $18.00, up 1.35% with strong technical momentum and bullish moving average signals. The company shows accelerating revenue growth, improving margins, and consistent earnings beats, with Q2 2026 revenue surging 28.8% and international sales up 67%. Recent news highlights international expansion momentum and raised 2026 guidance.
The outlook remains positive with analyst consensus pointing to 26% upside potential, though premium valuation metrics require continued execution. Key risks include rich P/E ratio of 54.6 and execution challenges in maintaining growth momentum amid competitive retail landscape.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
